Immucell CORP /DE/

ImmuCell Corporation announced preliminary unaudited sales results for Q2 2026, showing an 11.5% increase in total product sales compared to Q2 2025, driven by significant domestic sales growth.

ImmuCell Corporation announced the results of its 2026 Annual Meeting of Stockholders, where all proposals, including director elections and compensation plans, were approved.

ImmuCell Corporation announces a $3.5 million manufacturing expansion to boost First Defense product line output, starting immediately.

ImmuCell Corporation announced preliminary unaudited sales results for Q1 2026, showing a significant 28.4% increase in total product sales compared to the prior year.

ImmuCell Corporation announced the appointment of Kathy Turner, a seasoned animal health executive, to its Board of Directors, effective April 1, 2026.

ImmuCell Corporation announced unaudited financial results for 2025, reporting a significant increase in net operating income and a reduced net loss, driven by improved gross margins and strategic focus on its First Defense franchise.

ImmuCell Corporation's Q2 2026 results show significant revenue and net income increases, driven by First Defense product sales and strategic operational adjustments.

ImmuCell Corporation reported a significant financial turnaround in Q3 2025, moving from a net loss to net income, driven by improved gross margins and reduced product development expenses, despite ongoing Re-Tain commercialization challenges.

ImmuCell Corporation reported a significant turnaround in its second quarter 2025 financial results, driven by robust First Defense product sales and improved gross margins, while navigating ongoing Re-Tain regulatory challenges.

ImmuCell Corporation announces a profitable first quarter in 2025, driven by increased sales of its First Defense product line and improved gross margins.

ImmuCell Corporation saw a significant increase in sales and a reduction in net losses for the third quarter of 2024, driven by strong demand for its First Defense product line.

ImmuCell Corporation saw a significant increase in product sales during the second quarter of 2024 compared to the same period last year, but the company still reported a net loss.

ImmuCell Corporation has refiled its 2025 Stock Option and Incentive Plan, detailing its purpose, administration, eligibility, and provisions for stock options.

ImmuCell Corporation's 10-K filing reveals a significant increase in First Defense product sales and provides updates on the regulatory pathway for Re-Tain, its novel mastitis treatment.

ImmuCell Corporation's annual report details a year of production setbacks and strategic investments, while highlighting progress in the development of Re-Tain.

Director Kathy V. Turner was granted 17,899 non-qualified stock options as compensation for board service.

Director David Scott Tomsche was granted 11,933 non-qualified stock options as compensation for board service.

Director Gloria F. Basse was granted 11,933 non-qualified stock options as compensation for board service.

Director Paul R. Wainman was granted 11,933 non-qualified stock options as compensation for board service.

Immurcell Corp director Bryan K. Gathagan acquired 10,000 stock options as compensation for board services.

Immurcell Corporation reports a grant of 10,000 stock options to Director Paul R. Wainman.

ImmuCell Corporation is holding its Annual Meeting of Stockholders on June 11, 2026, to elect directors, vote on executive compensation, approve stock plans, amend its charter, and ratify its accounting firm.

ImmuCell Corporation will hold its Annual Meeting of Stockholders remotely on June 12, 2025, to vote on director elections, executive compensation, a stock option plan amendment, and the ratification of the independent accounting firm.

ImmuCell Corporation will hold its Annual Meeting of Stockholders remotely on June 13, 2024, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

Ejnar A. Knudsen III has increased his beneficial ownership in ImmuCell Corporation to 9.21% following a compulsory redemption of limited partners in Craton Capital, LP.